Downregulation of neurofibromin expression levels has been suggested to be involved in the resistance to anticancer drugs caused by hyperactivation of Ras/ERK signaling in NF1-associated MPNST cells [38], clear cell kidney cancer cells [39], mouse embryonic fibroblasts, and mouse neurofibroma-associated Schwann cells [40]. The gene discussed is NF1; the disease is plexiform neurofibroma.